{"hands_on_practices": [{"introduction": "The journey of a growth factor signal begins with a physical interaction: binding to a specific receptor on the cell surface. This initial step is not an all-or-nothing event; its intensity is governed by the concentration of the growth factor and its binding affinity for the receptor, described by the dissociation constant $K_d$. This exercise [@problem_id:4452520] provides a quantitative foundation for understanding signal initiation by tasking you with calculating receptor occupancy, a direct measure of how strongly a population of cells is being stimulated.", "problem": "In the context of cutaneous wound healing, keratinocytes at the wound edge rely on signaling by Epidermal Growth Factor (EGF) binding to the Epidermal Growth Factor Receptor (EGFR) to initiate proliferative and migratory responses. Consider a homogeneous extracellular environment in which EGF is present at a constant concentration of $1$ nanomolar (nM), maintained by a large reservoir relative to the number of receptors on the cell surface. Assume non-cooperative, single-site binding of EGF to EGFR, fast equilibration, and that receptor concentration is sufficiently low such that the free ligand concentration is well approximated by the total ligand concentration. The dissociation constant for the EGF–EGFR interaction is $K_{d} = 0.5$ nM.\n\nStarting from the law of mass action and the definition of the dissociation constant $K_{d}$ for the equilibrium $R + L \\rightleftharpoons RL$, and using conservation of receptor concentration, derive the equilibrium fraction of occupied receptors and compute its value under the stated conditions. Interpret this fraction as the likelihood of downstream EGFR activation across the cell population under the assumption that activation is proportional to receptor occupancy.\n\nExpress your final answer as a dimensionless decimal fraction, and round your answer to four significant figures.", "solution": "The problem is scientifically grounded, well-posed, and objective. It describes a classic bimolecular binding equilibrium, a fundamental concept in biochemistry and pharmacology, using realistic parameters for the Epidermal Growth Factor (EGF) and its receptor (EGFR). The assumptions provided are standard for simplifying this type of system and are internally consistent. All necessary information for a unique solution is provided. Therefore, the problem is valid.\n\nThe task is to derive the equilibrium fraction of occupied receptors and compute its value. The derivation begins from the law of mass action for the specified binding equilibrium.\n\nThe reversible binding of a ligand, $L$ (EGF), to a receptor, $R$ (EGFR), to form a receptor-ligand complex, $RL$, is described by the reaction:\n$$\nR + L \\rightleftharpoons RL\n$$\nAt equilibrium, the dissociation constant, $K_d$, is defined as the ratio of the product of the concentrations of the free reactants to the concentration of the complex:\n$$\nK_d = \\frac{[R][L]}{[RL]}\n$$\nwhere $[R]$ is the concentration of free receptors, $[L]$ is the concentration of free ligand, and $[RL]$ is the concentration of the receptor-ligand complex.\n\nThe total concentration of receptors, $[R]_T$, is conserved. It is the sum of the concentration of free receptors and the concentration of ligand-bound receptors:\n$$\n[R]_T = [R] + [RL]\n$$\nWe wish to determine the fraction of occupied receptors, which we denote as $\\theta$. This fraction is defined as the ratio of the concentration of occupied receptors to the total concentration of receptors:\n$$\n\\theta = \\frac{[RL]}{[R]_T}\n$$\nTo derive an expression for $\\theta$ in terms of $[L]$ and $K_d$, we first rearrange the receptor conservation equation to express the concentration of free receptors, $[R]$, in terms of $[R]_T$ and $[RL]$:\n$$\n[R] = [R]_T - [RL]\n$$\nNext, we substitute this expression for $[R]$ into the definition of the dissociation constant:\n$$\nK_d = \\frac{([R]_T - [RL])[L]}{[RL]}\n$$\nNow, we rearrange this equation to solve for the fraction $\\theta = \\frac{[RL]}{[R]_T}$.\nFirst, multiply both sides by $[RL]$:\n$$\nK_d [RL] = ([R]_T - [RL])[L]\n$$\nDistribute $[L]$ on the right-hand side:\n$$\nK_d [RL] = [R]_T [L] - [RL][L]\n$$\nGroup all terms containing $[RL]$ on one side of the equation:\n$$\nK_d [RL] + [RL][L] = [R]_T [L]\n$$\nFactor out $[RL]$ on the left-hand side:\n$$\n[RL](K_d + [L]) = [R]_T [L]\n$$\nFinally, to obtain the desired fraction $\\frac{[RL]}{[R]_T}$, we divide both sides by $[R]_T$ and by $(K_d + [L])$:\n$$\n\\theta = \\frac{[RL]}{[R]_T} = \\frac{[L]}{K_d + [L]}\n$$\nThis is the derived expression for the equilibrium fraction of occupied receptors, often referred to as the Hill-Langmuir equation for non-cooperative binding.\n\nNow, we compute the numerical value of this fraction using the provided data.\nThe dissociation constant is given as $K_d = 0.5$ nM.\nThe total ligand concentration is given as $1$ nM. The problem states that the receptor concentration is sufficiently low such that the free ligand concentration, $[L]$, can be approximated by the total ligand concentration.\nTherefore, we set $[L] \\approx 1$ nM.\n\nSubstituting these values into the derived equation for $\\theta$:\n$$\n\\theta = \\frac{1 \\text{ nM}}{0.5 \\text{ nM} + 1 \\text{ nM}} = \\frac{1 \\text{ nM}}{1.5 \\text{ nM}} = \\frac{1}{1.5} = \\frac{2}{3}\n$$\nAs a decimal, this value is $0.6666...$. Rounding to four significant figures as requested gives:\n$$\n\\theta \\approx 0.6667\n$$\nThis dimensionless fraction represents that at equilibrium, approximately $66.67\\%$ of the total EGFR population on the keratinocyte surface is occupied by EGF. The problem posits that downstream activation is proportional to receptor occupancy. Under this assumption, this fraction can be interpreted as the strength of the proliferative and migratory signal induced by EGF. Since the ligand concentration ($1$ nM) is twice the value of the dissociation constant ($0.5$ nM), the system is significantly activated, consistent with the potent role of EGF in stimulating wound repair.", "answer": "$$\n\\boxed{0.6667}\n$$", "id": "4452520"}, {"introduction": "While understanding individual pathways is crucial, a key skill in pathology is diagnosing complex failures in a living system. In this scenario [@problem_id:4452497], you are presented with a case of impaired wound healing and a comprehensive dataset mimicking a real preclinical study. Your challenge is to act as a detective, integrating histological, biochemical, and functional evidence to pinpoint the rate-limiting defect in the growth factor signaling network and propose a logical therapeutic strategy.", "problem": "A full-thickness skin wound model in a laboratory mouse shows delayed re-epithelialization despite an intact granulation bed. The student is asked to infer the rate-limiting growth factor axis and propose a targeted correction strategy, reasoning from first principles of tissue repair and growth factor signaling. The following observations are provided and were reproducible across $n=4$ animals:\n\n- Histology at $48$ hours: basal keratinocytes at the wound edge express the stem cell marker $p63$, but the proliferation index (Ki-$67$) is reduced to $5\\%$ (control: $25\\%$). Leading-edge keratinocyte migration distance is $30$ $\\mu$m (control: $120$ $\\mu$m).\n- Wound fluid assay at $24$ hours: Epidermal Growth Factor (EGF) $\\approx 2$ ng/mL (control: $\\approx 20$ ng/mL), transforming growth factor-$\\alpha$ (TGF-$\\alpha$) $\\approx 0.5$ ng/mL (control: $\\approx 5$ ng/mL), amphiregulin $\\approx 1$ ng/mL (control: $\\approx 8$ ng/mL). Keratinocyte Growth Factor (KGF; Fibroblast Growth Factor-$7$) $\\approx 10$ ng/mL (control: $\\approx 10$ ng/mL). Fibroblast Growth Factor-$10$ $\\approx 8$ ng/mL (control: $\\approx 8$ ng/mL). Hepatocyte Growth Factor (HGF) $\\approx 12$ ng/mL (control: $\\approx 12$ ng/mL). Transforming Growth Factor-$\\beta 1$ (TGF-$\\beta 1$) $\\approx 10$ ng/mL (control: $\\approx 2$ ng/mL). Vascular Endothelial Growth Factor (VEGF) $\\approx 25$ ng/mL (control: $\\approx 20$ ng/mL). Platelet-Derived Growth Factor-BB (PDGF-BB) $\\approx 15$ ng/mL (control: $\\approx 15$ ng/mL).\n- Receptor expression by immunoblot of wound-edge epidermis at $24$ hours: Epidermal Growth Factor Receptor (EGFR) is $\\approx 50\\%$ of control, Fibroblast Growth Factor Receptor-2b (FGFR2b) is near control ($\\approx 90\\%$), c-Met (HGF receptor) is near control ($\\approx 95\\%$).\n- Signaling in keratinocytes at wound edge: phosphorylated extracellular signal-regulated kinase (pERK)/total ERK ratio $\\approx 0.2$ (control: $\\approx 0.8$), phosphorylated protein kinase B (pAKT)/total AKT ratio $\\approx 0.3$ (control: $\\approx 0.7$), phosphorylated mothers against decapentaplegic homolog $2/3$ (pSMAD$2/3$) levels are elevated relative to control.\n- Angiogenesis markers (CD$31^+$ area) are normal to increased; fibroblast density and collagen deposition at $72$ hours are comparable to control.\n\nAn in vitro scratch assay using primary mouse keratinocytes and pooled wound fluid reproduces the migration delay. Addition of recombinant EGF at $10$ ng/mL restores closure speed to near control, whereas addition of recombinant KGF at $10$ ng/mL does not.\n\nStarting from core definitions of the phases of wound healing (hemostasis, inflammation, proliferation, remodeling) and the role of keratinocyte stem cells in re-epithelialization, and using first principles of ligand-receptor signaling and growth factor-specific effects on cell cycle and migration, which of the following identifies the rate-limiting growth factor axis and proposes the most direct targeted correction strategy for the delayed epithelial closure?\n\nA. Epidermal Growth Factor Receptor (EGFR) axis is rate-limiting; apply topical recombinant EGF to restore keratinocyte activation and migration.\n\nB. Vascular Endothelial Growth Factor (VEGF) axis is rate-limiting; inject VEGF to improve angiogenesis and thereby accelerate closure.\n\nC. Transforming Growth Factor-$\\beta$ (TGF-$\\beta$) axis is rate-limiting; neutralize TGF-$\\beta$ alone to relieve keratinocyte growth suppression.\n\nD. Keratinocyte Growth Factor (KGF; Fibroblast Growth Factor-$7$) axis is rate-limiting; deliver recombinant KGF to activate FGFR2b on keratinocytes.\n\nE. Platelet-Derived Growth Factor (PDGF) axis is rate-limiting; apply PDGF-BB gel to stimulate fibroblast proliferation and matrix deposition.", "solution": "The problem statement is subjected to validation prior to any attempt at a solution.\n\n### Step 1: Extract Givens\nThe explicit data and observations provided in the problem statement are as follows:\n\n- **Model:** Full-thickness skin wound in a laboratory mouse, with $n=4$ animals.\n- **Phenotype:** Delayed re-epithelialization with an intact granulation bed.\n- **Histology ($48$ hours):**\n    - Basal keratinocytes at the wound edge are $p63$ positive.\n    - Ki-$67$ proliferation index is $5\\%$ (control: $25\\%$).\n    - Keratinocyte migration distance is $30$ $\\mu$m (control: $120$ $\\mu$m).\n- **Wound Fluid Analysis ($24$ hours):**\n    - EGF: $\\approx 2$ ng/mL (control: $\\approx 20$ ng/mL).\n    - TGF-$\\alpha$: $\\approx 0.5$ ng/mL (control: $\\approx 5$ ng/mL).\n    - Amphiregulin: $\\approx 1$ ng/mL (control: $\\approx 8$ ng/mL).\n    - KGF (FGF-$7$): $\\approx 10$ ng/mL (control: $\\approx 10$ ng/mL).\n    - FGF-$10$: $\\approx 8$ ng/mL (control: $\\approx 8$ ng/mL).\n    - HGF: $\\approx 12$ ng/mL (control: $\\approx 12$ ng/mL).\n    - TGF-$\\beta 1$: $\\approx 10$ ng/mL (control: $\\approx 2$ ng/mL).\n    - VEGF: $\\approx 25$ ng/mL (control: $\\approx 20$ ng/mL).\n    - PDGF-BB: $\\approx 15$ ng/mL (control: $\\approx 15$ ng/mL).\n- **Receptor Expression (Immunoblot, $24$ hours, wound-edge epidermis):**\n    - EGFR: $\\approx 50\\%$ of control.\n    - FGFR2b: $\\approx 90\\%$ of control.\n    - c-Met: $\\approx 95\\%$ of control.\n- **Intracellular Signaling (Keratinocytes, wound edge):**\n    - pERK/total ERK ratio: $\\approx 0.2$ (control: $\\approx 0.8$).\n    - pAKT/total AKT ratio: $\\approx 0.3$ (control: $\\approx 0.7$).\n    - pSMAD$2/3$ levels: elevated relative to control.\n- **Other Tissue-level Observations:**\n    - Angiogenesis (CD$31^+$ area): normal to increased.\n    - Fibroblast density and collagen deposition ($72$ hours): comparable to control.\n- **In Vitro Functional Assay:**\n    - A scratch assay with primary keratinocytes and pooled wound fluid reproduces the migration delay.\n    - Addition of recombinant EGF at $10$ ng/mL restores closure speed.\n    - Addition of recombinant KGF at $10$ ng/mL does not restore closure speed.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is scientifically grounded, well-posed, and objective. It provides a comprehensive and internally consistent dataset from a standard preclinical model of wound healing. The measured analytes (growth factors, receptors, signaling proteins) and observed cellular processes (proliferation, migration, angiogenesis) are all fundamental to the field of tissue repair and pathology. The data values are plausible for biological assays. The logical structure of the problem—presenting a phenotype and multiple lines of mechanistic evidence to deduce a cause—is a standard scientific exercise. The problem is free of contradictions, ambiguities, and non-scientific claims.\n\n### Step 3: Verdict and Action\nThe problem statement is **valid**. A solution will be derived based on the provided data.\n\n### Derivation of Solution\nThe problem asks to identify the rate-limiting growth factor axis responsible for delayed re-epithelialization and propose a direct correction. Re-epithelialization is driven by the proliferation and migration of keratinocytes from the wound margins.\n\n1.  **Analyze the Phenotype:** The core defect is impaired keratinocyte function. Histology shows that keratinocyte stem/progenitor cells are present (positive for the marker $p63$), but their proliferation is severely reduced (Ki-$67$ index is $5\\%$ vs. $25\\%$ control), and their migration is drastically impaired (migration distance is $30$ $\\mu$m vs. $120$ $\\mu$m control). The fact that the granulation bed, angiogenesis, and fibroblast activity are normal or near-normal focuses the problem specifically on the epidermal component of healing.\n\n2.  **Analyze Growth Factor and Receptor Levels:**\n    - **Epidermal Growth Factor Receptor (EGFR) Axis:** There is a profound defect in this axis. The primary ligands for EGFR—EGF, TGF-$\\alpha$, and amphiregulin—are all reduced by approximately an order of magnitude ($\\approx 90\\%$). Furthermore, the expression of the receptor itself, EGFR, on the target keratinocytes is reduced by $50\\%$. This represents a compounding deficit in both the signal (ligands) and the cell's ability to receive it (receptor).\n    - **Keratinocyte Growth Factor (KGF) Axis:** The ligand KGF (FGF-$7$) and another related ligand, FGF-$10$, are present at normal levels. The corresponding receptor, FGFR2b, is also expressed at near-normal levels ($\\approx 90\\%$). This axis appears grossly intact.\n    - **Hepatocyte Growth Factor (HGF) Axis:** The ligand HGF and its receptor c-Met are both at normal levels. This axis is also intact.\n    - **Transforming Growth Factor-$\\beta$ (TGF-$\\beta$) Axis:** The ligand TGF-$\\beta 1$ is significantly elevated ($10$ ng/mL vs. $2$ ng/mL control). TGF-$\\beta$ is a known potent inhibitor of keratinocyte proliferation and migration. This suggests a state of active suppression on the keratinocytes.\n    - **Other Axes (VEGF, PDGF):** VEGF is normal to elevated, and PDGF-BB is normal. This aligns with the observation of normal angiogenesis and fibroblast function, respectively, and indicates they are not the source of the epithelial defect.\n\n3.  **Analyze Intracellular Signaling:**\n    - The signaling pathways downstream of EGFR are the Ras-MAPK (leading to ERK phosphorylation) and PI3K-AKT pathways. The data shows that both pERK/ERK and pAKT/AKT ratios are severely reduced. This is the direct molecular consequence of the diminished EGFR ligand availability and receptor expression. Reduced pERK activity correlates with decreased proliferation, and reduced pAKT activity correlates with decreased migration and survival, perfectly explaining the observed cellular phenotype.\n    - The signaling pathway downstream of TGF-$\\beta$ is the SMAD pathway. The data shows that pSMAD$2/3$ levels are elevated, which is the direct molecular consequence of the increased TGF-$\\beta 1$ in the wound fluid. This confirms that the inhibitory TGF-$\\beta$ signal is being actively transduced by the keratinocytes.\n\n4.  **Synthesize with the Functional Assay:** The *in vitro* scratch assay is the decisive experiment.\n    - It confirms that soluble factors in the wound fluid are responsible for the keratinocyte migration defect.\n    - The fact that adding recombinant EGF at $10$ ng/mL restores normal function is a classic rescue experiment. It proves that the keratinocytes are intrinsically capable of migrating but lack the necessary activating signal. It directly implicates the deficiency in EGFR activation as the causal and rate-limiting defect.\n    - The failure of recombinant KGF to rescue the defect, despite an intact KGF/FGFR2b axis, further strengthens the conclusion that the EGFR axis is the critical bottleneck. The lack of rescue by KGF might be due to the overpowering inhibitory effect of TGF-$\\beta$, but the positive rescue by EGF shows that overcoming the EGFR deficit is sufficient.\n\n5.  **Conclusion:** The evidence overwhelmingly points to a dysfunctional EGFR signaling axis as the primary, rate-limiting cause of the delayed re-epithelialization. This is due to a severe lack of EGFR ligands and a partial reduction in EGFR itself. While elevated TGF-$\\beta$ is a significant contributing factor by actively suppressing keratinocytes, the deficiency in the primary mitogenic and motogenic driver (EGF) is identified as the rate-limiting step by the successful rescue experiment. The most direct targeted correction is to supply the missing stimulus, i.e., apply recombinant EGF.\n\n### Evaluation of Options\n\n**A. Epidermal Growth Factor Receptor (EGFR) axis is rate-limiting; apply topical recombinant EGF to restore keratinocyte activation and migration.**\nThis statement is fully supported by the integrated analysis. The deficiency in the EGFR axis (ligands, receptor, downstream signaling) directly explains the phenotype (impaired proliferation and migration). The *in vitro* rescue experiment provides definitive proof that this axis is rate-limiting and that applying EGF is a successful correction strategy.\n**Verdict: Correct.**\n\n**B. Vascular Endothelial Growth Factor (VEGF) axis is rate-limiting; inject VEGF to improve angiogenesis and thereby accelerate closure.**\nThis statement is contradicted by the data. VEGF levels and angiogenesis markers (CD$31^+$) are normal to increased. The problem is not with vascularization of the granulation bed but with the overlying epithelium.\n**Verdict: Incorrect.**\n\n**C. Transforming Growth Factor-$\\beta$ (TGF-$\\beta$) axis is rate-limiting; neutralize TGF-$\\beta$ alone to relieve keratinocyte growth suppression.**\nWhile the elevation of TGF-$\\beta 1$ and pSMAD$2/3$ indicates a significant inhibitory pressure, calling this axis \"rate-limiting\" is less precise than identifying the EGFR axis. The rate-limiting step is the \"slowest step,\" which in this case is the lack of a positive driving signal. The EGF rescue experiment demonstrates that restoring the positive signal is sufficient, making the EGFR axis the primary rate-limiting factor. Neutralizing TGF-$\\beta$ is a plausible therapeutic approach, but it addresses the \"brakes\" rather than the missing \"accelerator,\" which the data identifies as the critical failure.\n**Verdict: Incorrect.**\n\n**D. Keratinocyte Growth Factor (KGF; Fibroblast Growth Factor-$7$) axis is rate-limiting; deliver recombinant KGF to activate FGFR2b on keratinocytes.**\nThis statement is directly falsified by the evidence. KGF levels and FGFR2b receptor levels are normal. Crucially, the *in vitro* experiment shows that adding recombinant KGF *fails* to correct the migration defect.\n**Verdict: Incorrect.**\n\n**E. Platelet-Derived Growth Factor (PDGF) axis is rate-limiting; apply PDGF-BB gel to stimulate fibroblast proliferation and matrix deposition.**\nThis statement is contradicted by the data. PDGF-BB levels are normal, and the downstream effects (fibroblast density, collagen deposition) are also normal. PDGF primarily acts on mesenchymal cells, and the defect is clearly in the epithelial cells (keratinocytes).\n**Verdict: Incorrect.**", "answer": "$$\\boxed{A}$$", "id": "4452497"}, {"introduction": "Tissue repair is a dynamic process that unfolds over time, culminating in outcomes like scar formation. We can move from qualitative descriptions to quantitative predictions by using mathematical models to capture the underlying kinetics. This problem [@problem_id:4452517] challenges you to build such a model, using a differential equation to describe how collagen accumulates based on the balance between growth factor-driven fibroblast proliferation and matrix degradation, ultimately determining the final scar thickness.", "problem": "A granulation tissue region undergoing repair is influenced by Transforming Growth Factor beta (TGF-$\\beta$) and Platelet-Derived Growth Factor (PDGF), which stimulate proliferation of fibroblasts arising in part from mesenchymal stem cells. Assume that the fibroblast areal density evolves as $N(t)=N_0 \\exp(rt)$ for time $t \\geq 0$, where $N_0$ is the initial fibroblast number per unit area and $r$ is a constant proliferation rate induced by growth factors. Each fibroblast synthesizes collagen at a constant per-cell rate $s$ (mass per cell per unit time). Concurrently, already-deposited collagen is degraded by Matrix Metalloproteinase (MMP) activity approximated as first-order loss with respect to existing collagen, with rate constant $\\lambda$. Let $M(t)$ denote the collagen mass per unit area present at time $t$, and let $\\rho$ be the volumetric density of collagen (mass per unit volume), so that the scar thickness satisfies $h(t)=M(t)/\\rho$ under the assumption of uniform density and composition.\n\nStarting from conservation of mass for collagen, namely that the time rate of change of $M(t)$ equals production by fibroblasts minus first-order degradation, derive a closed-form expression for the scar thickness $h(T)$ at a fixed time $T>0$ in terms of $N_0$, $r$, $s$, $\\lambda$, $\\rho$, and $T$. Express the final thickness in meters. Your final answer must be a single closed-form analytic expression. Do not substitute numerical values.", "solution": "The problem requires deriving an expression for the scar thickness, $h(t)$, based on a mass conservation principle for collagen.\n\nThe principle of conservation of mass for collagen, $M(t)$, is stated as:\n$$\n\\frac{dM(t)}{dt} = (\\text{Rate of Production}) - (\\text{Rate of Degradation})\n$$\nThe rate of collagen production is the product of the number of fibroblasts per unit area, $N(t)$, and the per-cell synthesis rate, $s$.\n$$\n\\text{Rate of Production} = N(t) \\cdot s = (N_0 \\exp(rt)) \\cdot s = s N_0 \\exp(rt)\n$$\nThe rate of collagen degradation is given as a first-order loss with respect to the existing collagen mass per unit area, $M(t)$, with a rate constant $\\lambda$.\n$$\n\\text{Rate of Degradation} = \\lambda M(t)\n$$\nSubstituting these terms into the mass balance equation gives the governing ordinary differential equation (ODE) for $M(t)$:\n$$\n\\frac{dM}{dt} = s N_0 \\exp(rt) - \\lambda M\n$$\nThis is a first-order linear non-homogeneous ordinary differential equation. We can rewrite it in standard form:\n$$\n\\frac{dM}{dt} + \\lambda M = s N_0 \\exp(rt)\n$$\nTo solve this equation, we use the method of integrating factors. The integrating factor, $I(t)$, is given by:\n$$\nI(t) = \\exp\\left(\\int \\lambda dt\\right) = \\exp(\\lambda t)\n$$\nMultiplying the entire ODE by the integrating factor $I(t)$:\n$$\n\\exp(\\lambda t) \\frac{dM}{dt} + \\lambda \\exp(\\lambda t) M = s N_0 \\exp(rt) \\exp(\\lambda t)\n$$\nThe left-hand side is the derivative of the product $M(t) \\exp(\\lambda t)$ with respect to $t$, according to the product rule for differentiation.\n$$\n\\frac{d}{dt} \\left( M(t) \\exp(\\lambda t) \\right) = s N_0 \\exp((r+\\lambda)t)\n$$\nTo find $M(t)$, we integrate both sides with respect to $t$:\n$$\n\\int \\frac{d}{dt} \\left( M(t) \\exp(\\lambda t) \\right) dt = \\int s N_0 \\exp((r+\\lambda)t) dt\n$$\n$$\nM(t) \\exp(\\lambda t) = \\frac{s N_0}{r+\\lambda} \\exp((r+\\lambda)t) + C\n$$\nwhere $C$ is the constant of integration. This step assumes $r+\\lambda \\neq 0$. Physically, $r$ is a proliferation rate and $\\lambda$ is a degradation rate constant, so $r \\ge 0$ and $\\lambda \\ge 0$. The case $r+\\lambda = 0$ would only occur if $r=0$ and $\\lambda=0$, which implies no cell proliferation and no matrix degradation, a trivial case. We proceed assuming $r+\\lambda > 0$.\n\nTo determine the constant $C$, we must apply an initial condition. The problem describes the formation of granulation tissue and scar, a process starting from an initial state. It is physically necessary to assume that at time $t=0$, the amount of newly synthesized scar collagen is zero. Therefore, we set the initial condition $M(0)=0$.\nSubstituting $t=0$ and $M(0)=0$ into the integrated equation:\n$$\nM(0) \\exp(\\lambda \\cdot 0) = \\frac{s N_0}{r+\\lambda} \\exp((r+\\lambda) \\cdot 0) + C\n$$\n$$\n0 \\cdot 1 = \\frac{s N_0}{r+\\lambda} \\cdot 1 + C\n$$\n$$\nC = -\\frac{s N_0}{r+\\lambda}\n$$\nNow, substitute the value of $C$ back into the expression for $M(t) \\exp(\\lambda t)$:\n$$\nM(t) \\exp(\\lambda t) = \\frac{s N_0}{r+\\lambda} \\exp((r+\\lambda)t) - \\frac{s N_0}{r+\\lambda}\n$$\n$$\nM(t) \\exp(\\lambda t) = \\frac{s N_0}{r+\\lambda} \\left( \\exp((r+\\lambda)t) - 1 \\right)\n$$\nTo obtain the final expression for $M(t)$, we divide by $\\exp(\\lambda t)$:\n$$\nM(t) = \\frac{s N_0}{r+\\lambda} \\left( \\frac{\\exp((r+\\lambda)t) - 1}{\\exp(\\lambda t)} \\right) = \\frac{s N_0}{r+\\lambda} \\left( \\exp(rt) - \\exp(-\\lambda t) \\right)\n$$\nThe problem asks for the scar thickness, $h(t)$, which is related to the collagen mass per unit area, $M(t)$, and the collagen density, $\\rho$, by $h(t) = M(t)/\\rho$.\n$$\nh(t) = \\frac{M(t)}{\\rho} = \\frac{1}{\\rho} \\left( \\frac{s N_0}{r+\\lambda} \\right) \\left( \\exp(rt) - \\exp(-\\lambda t) \\right)\n$$\nFinally, we evaluate the thickness at the specific time $t=T$:\n$$\nh(T) = \\frac{s N_0}{\\rho(r+\\lambda)} \\left( \\exp(rT) - \\exp(-\\lambda T) \\right)\n$$\nThis is the closed-form analytical expression for the scar thickness at time $T$. The problem asks to express this in meters, and our dimensional analysis has confirmed the expression has units of length.", "answer": "$$\n\\boxed{\\frac{s N_0}{\\rho (r + \\lambda)} \\left( \\exp(rT) - \\exp(-\\lambda T) \\right)}\n$$", "id": "4452517"}]}